Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis
Détails
ID Serval
serval:BIB_024F78E3019E
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis
Périodique
European Journal of Neurology
ISSN
1351-5101 (Print)
Statut éditorial
Publié
Date de publication
11/2005
Volume
12
Numéro
11
Pages
869-78
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Nov
Research Support, Non-U.S. Gov't --- Old month value: Nov
Résumé
Glatiramer acetate (GA) treatment for relapsing remitting multiple sclerosis (RRMS) leads to decreased GA-specific proliferative responses and a Th2 cytokine shift. To study a possible correlation between immunological and clinical responses to GA therapy, we prospectively followed RRMS patients clinically, by magnetic resonance imaging and by primary immunological assays. Fluctuation of GA-specific proliferative responses was significantly lower in treatment responders than in untreated patients, and GA-specific proliferative responses were increased during relapses. These associations suggest a possible causal relationship between immunological and clinical responses to GA therapy. Primary proliferation assays may thus be a useful marker for treatment response.
Mots-clé
Adult
Biological Markers/analysis
Cytokines/*secretion
Humans
*Immune Tolerance
Magnetic Resonance Imaging
Middle Aged
Multiple Sclerosis, Relapsing-Remitting/*drug therapy/immunology
Peptides/*therapeutic use
Prospective Studies
Th2 Cells
Treatment Outcome
Pubmed
Web of science
Création de la notice
25/01/2008 12:46
Dernière modification de la notice
20/08/2019 12:24